Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (69)

I-01

Modelling of Dexamethasone in Paediatric Leukaemia Patients using a Population Pharmacokinetic Approach

Wednesday 10:30-12:00

I-02Klaus Lindauer

Model Simplification

Wednesday 10:30-12:00

I-03Dan Liu

Application of Global Sensitivity Analysis Methods to Determine the most Influential Parameters of a Minimal PBPK Model of Quinidine

Wednesday 10:30-12:00

I-04Rocio Lledo

PK/PD modelling of an anti-FcRn mAb to optimise FIM design – translation from cyno to human

Wednesday 10:30-12:00

I-05Florence Loingeville

Using Hamiltonian Monte-Carlo to design longitudinal count studies accounting for parameter and model uncertainties

Wednesday 10:30-12:00

I-06Amelia Deitchman

Tigecycline-Tetracycline Combination Modeling against Pseudomonas aeruginosa: Application of the General Pharmacodynamic Interaction Term in Various Interaction Models

Wednesday 10:30-12:00

I-07Dominik Lott

Tolerance modeling: effects of the selective S1P1 receptor modulator ponesimod on heart rate

Wednesday 10:30-12:00

I-08Rubin Lubomirov

Population pharmacokinetic-based interspecies allometric scaling and prediction of first-in-human (FIH) pharmacokinetics of a new anticancer agent

Wednesday 10:30-12:00

I-09Inga Ludwig

Correlative analysis of response to treatment and biomarker levels in a setting with a time-to-event efficacy outcome and sparse biomarker data

Wednesday 10:30-12:00

I-10John C Lukas

Order in patch absorption rates?

Wednesday 10:30-12:00

I-11Sreenath M Krishnan

Influence of the number of tumor size measurements on model-derived tumor size metrics and prediction of survival

Wednesday 10:30-12:00

I-12Lei Ma

Dupilumab dose selection for a phase 3 study in asthma patients: pharmacokinetic/pharmacodynamic (PK/PD) modelling and clinical trial simulation

Wednesday 10:30-12:00

I-13Vincent Madelain

Modeling viral kinetics predicts a rapid establishment of the cytotoxic immune response targeting distinct infected cell compartments in SIV controller macaques (ANRS SIC study)

Wednesday 10:30-12:00

I-14Paolo Magni

Execution of complex Bayesian workflows with the DDMoRe Interoperability Framework: a case study in the diabetes area

Wednesday 10:30-12:00

I-15Corinna Maier

Robust parameter estimation for dynamical systems from outlier-corrupted data

Wednesday 10:30-12:00

I-16Victor Mangas-Sanjuan

Semi-mechanistic Pharmacodynamic model of complex receptor-hormone dynamics

Wednesday 10:30-12:00

I-17Ben Margetts

Modelling Cytomegalovirus Growth Kinetics in Immunocompromised Children

Wednesday 10:30-12:00

I-18Dimitris Maris

Asymptotic Analysis on a TMDD model: Control of the process

Wednesday 10:30-12:00

I-19

Using mixed effects modelling improves detection of drug-gene interactions in mouse trials

Wednesday 10:30-12:00

I-20Paolo Mazzei

Translational model-based approach to assist the dose-range selection of an antibody-drug conjugate entering Phase I

Wednesday 10:30-12:00

I-21Nicola Melillo

Multiscale mechanistic models in Systems Pharmacology: development of a model describing Atorvastatin pharmacokinetics through integration of metabolic network in Physiologically Based Pharmacokinetic models.

Wednesday 10:30-12:00

I-22Sandrine Micallef

Evaluation of tumor kinetics metrics as early endpoint to support decision making in early drug development

Wednesday 10:30-12:00

I-23Joske Millecam

A new approach in pediatric drug design: the development of a pediatric pig model. Part II: The maturation of hepatic cytochrome P450 enzymes using enzyme activity and proteomics

Wednesday 10:30-12:00

I-24Jonathan Mochel

One Health: Translational and Reverse Translational Modeling of Inflammatory Bowel Disease using an advanced Boolean Network

Wednesday 10:30-12:00

I-25

Application of a physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat to improve dosing regimens in adults

Wednesday 10:30-12:00

I-26Tadakatsu Nakamura

Population Pharmacokinetic Analysis of Compound A and Its Metabolite in Healthy Subjects and Patients with Diabetic Nephropathy

Wednesday 10:30-12:00

I-27Srividya Neelakantan

Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects with Severe Hemophilia A Across All Ages

Wednesday 10:30-12:00

I-28Asuka Suzuki

A Bayesian approach for population pharmacokinetic modeling of alcohol in Japanese Subjects

Wednesday 10:30-12:00

I-29Thu Thuy Nguyen

Population pharmacodynamic model of bronchodilator response to salbutamol in wheezy preschool children

Wednesday 10:30-12:00

I-30Rikard Nordgren

Calling C functions from NONMEM

Wednesday 10:30-12:00

I-31Ana Novakovic

A longitudinal model linking absolute lymphocyte count (ALC) and volume of T2 lesions to expanded disability status scale (EDSS) in patients with relapsing-remitting multiple sclerosis (RRMS)

Wednesday 10:30-12:00

I-32Kayode Ogungbenro

Sparse sampling design for characterizing individual PK of recombinant factor VIII fusion protein (rFVIIIFc) in prophylactic treatment of Hemophilia A

Wednesday 10:30-12:00

I-33Boram Ohk

Population Pharmacokinetics of Tacrolimus in Healhty Korean Subjects:role of CYP3A5 genotype and metabolite

Wednesday 10:30-12:00

I-34Olafuyi Olusola

The Use of Physiologically Based Pharmacokinetic Modelling in Assessing Drug–drug Interactions Associated with Antimalarial Treatment in Paediatrics Co-infected with Tuberculosis: A Case Study with Lumefantrine and Rifampicin.

Wednesday 10:30-12:00

I-35Sean Oosterholt

PKPD modelling of MYCN-inhibition in vitro and in vivo in a mouse model of neuroblastoma

Wednesday 10:30-12:00

I-36- -

Investigation of Bayesian inference in predicting tissue concentrations using RStan

Wednesday 10:30-12:00

I-37Maria Panselina

Dose-saturable model for amoxicillin used to predict probability of response in normal and obese pediatrics

Wednesday 10:30-12:00

I-38Sang-In Park

Population pharmacokinetic analysis of evogliptin in subjects with varying degrees of renal function

Wednesday 10:30-12:00

I-39Zinnia Parra-Guillen

Exploring the impact of study design on unperturbed tumour growth inhibition modelling

Wednesday 10:30-12:00

I-40Christophe Passot

In-depth assessment of the influence of anti-drug antibodies on adalimumab pharmacokinetics and concentration-effect relationship in rheumatoid arthritis

Wednesday 10:30-12:00

I-41

Informing modeling and clinical trial simulation using the real world data: data content, quality and availability assessment

Wednesday 10:30-12:00

I-42Dimitrios Patsatzis

Construction and evaluation of “global” Micahelis-Menten reduced models

Wednesday 10:30-12:00

I-43Sophie Peigné

How to handle non-linearity in absorption: a case study in oncology

Wednesday 10:30-12:00

I-44Nathalie Perdaems

Multi-species translational PK/PD modelling in type 2 diabetes

Wednesday 10:30-12:00

I-45Belén Pérez Solans

Modelling tumour growth and progression free survival of breast cancer patients treated with neoadjuvant therapy

Wednesday 10:30-12:00

I-46Jonás Samuel Pérez-Blanco

Population PK and exposure-response analysis of sleep parameters for JNJ-42847922, a novel Orexin 2 receptor antagonist

Wednesday 10:30-12:00

I-47Carlos Perez-Ruixo

Identifying lack of adherence to antipsychotic treatment using plasma concentrations measurements

Wednesday 10:30-12:00

I-48Chiara Piana

A model-based approach to extrapolate drug-drug interactions from rats to humans

Wednesday 10:30-12:00

I-49Philippe Pierrillas

Application of Model-Based Adaptive Optimal Design to determine a recommended dosing regimen for combination therapy in oncology

Wednesday 10:30-12:00

I-50Nikhil Pillai

Estimating Nonlinear Dynamic Systems in Pharmacology using Chaos Synchronization

Wednesday 10:30-12:00

I-51Italo Poggesi

A Shiny App for the Probability of Technical Success of a New Molecular Entity in the Preclinical to Clinical Translational Phase

Wednesday 10:30-12:00

I-52Sebastian Polak

Physiologically based pharmacokinetic model (PBPK) for the halofantrine cardiac effect prediction – proof of concept study towards the system for the antimalarial drugs cardiac safety assessment.

Wednesday 10:30-12:00

I-53Manuel Prado-Velasco

PBPK versus PK modeling of Tacrolimus drug in patients with renal transplant as knowledge engines for personalized posology software: PhysPK® development and preliminary results

Wednesday 10:30-12:00

I-54Tim Preijers

Population pharmacokinetic analysis of perioperative factor IX dosing in hemophilia B

Wednesday 10:30-12:00

I-55Angelica Quartino

Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3

Wednesday 10:30-12:00

I-56Christian Hove Claussen

PharmTeX: a LaTeX-based open-source platform for automated reporting workflow

Wednesday 10:30-12:00

I-57Theo Reijmers

Population PK Modeling of Dapivirine released from Vaginal Rings

Wednesday 10:30-12:00

I-58Didier Renard

Label extension for canakinumab in Adult Onset Still’s Disease (AOSD) – Extrapolation from pediatrics to adults

Wednesday 10:30-12:00

I-59Christer Rimmler

Development of a PBPK model to predict the pharmacokinetics of cefuroxime during surgery

Wednesday 10:30-12:00

I-60Christelle Rodrigues

Population pharmacokinetics of the sustained-release granule formulation of valproic acid in epileptic children

Wednesday 10:30-12:00

I-61Amin Rostami

Predicting diclofenac systemic and synovial fluid concentrations after dermal application using the Multi-Phase Multi-Layer MechDermA PBPK model

Wednesday 10:30-12:00

I-62Hauke Ruehs

Exposure-response analysis of vilaprisan describing uterine fibroid size by population PK/PD modelling

Wednesday 10:30-12:00

I-63Leire Ruiz Cerdá

Modeling of Interferon effector pathway after viral infection

Wednesday 10:30-12:00

I-64Alberto Russu

Dose-conversion factors for risperidone and paliperidone formulations based on steady-state PK similarity

Wednesday 10:30-12:00

I-65Sunae Ryu

Population pharmacokinetic model of propranolol and its metabolite reflecting the first-pass effect in patients with hepatic impairment

Wednesday 10:30-12:00

I-66Muhammad Waqas Sadiq

A model-based comparison of absorption pharmacokinetics for a selective glucocorticoid receptor modulator administered with different inhalation devices

Wednesday 10:30-12:00

I-68Mark Sale

Application of global search methods for parameter estimation in models with poorly defined objective function surfaces

Wednesday 10:30-12:00

I-69Franziska Schädeli Stark

Assessing the adequacy of a minimal PK sampling schedule for individual dose adjustment decisions in a proof of mechanism (PoM) study in a special population

Wednesday 10:30-12:00

I-70Stein Schalkwijk

Placental Transfer of Darunavir and Simulation of Fetal Exposure

Wednesday 10:30-12:00